From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.
Harrer A, Pilz G, Oppermann K, Sageder M, Afazel S, Haschke-Becher E, Rispens T, de Vries A, McCoy M, Stevanovic V, Hitzl W, Trinka E, Kraus J, Sellner J, Wipfler P.
Harrer A, et al. Among authors: kraus j.
Clin Immunol. 2017 Mar;176:87-93. doi: 10.1016/j.clim.2017.01.001. Epub 2017 Jan 17.
Clin Immunol. 2017.
PMID: 28108364